A green tea polyphenol called epigallocatechin-3-gallate (EGCG) when combined with low doses of COX-2 inhibitor celecoxib, could slow the progression of human prostate cancer.
Such were the findings of researchers from University of Wisconsin-Madison reported in the March 1 issue of Clinical Cancer Research.
According to Hasan Mukhtar, Ph.D., professor of dermatology at the University of Wisconsin and member of Wisconsin’s Paul Carbone Comprehensive Cancer Center:
“Celecoxib and green tea have a synergistic effect — each triggering cellular pathways that, combined, are more powerful than either agent alone. We hope that a clinical trial could lead to a preventative treatment as simple as …read more